<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00946699</url>
  </required_header>
  <id_info>
    <org_study_id>MI-CP200</org_study_id>
    <nct_id>NCT00946699</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Tolerability of MEDI-551 in Scleroderma</brief_title>
  <official_title>A Phase 1, Randomized, Double-blind, Placebo-controlled Study of the Safety and Tolerability of MEDI-551 in Scleroderma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety and tolerability of
      intravenously administered MEDI-551 over escalating single doses in adult subjects with
      Scleroderma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the safety and tolerability of escalating single IV doses of MEDI-551 in adult
      subjects with scleroderma who have at least moderate skin thickening in an area suitable for
      repeat biopsy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The safety and tolerability of MEDI-551 will be assessed primarily by summarizing treatment-emergent AEs and SAEs.</measure>
    <time_frame>Day 85</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary endpoints of the study are to assess the PK, IM, and PD of single IV doses of MEDI-551 in adult subjects with scleroderma. Pharmacodynamics will be assessed by numbers of B cells in blood and skin.</measure>
    <time_frame>Day 85</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Scleroderma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI-551</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI-551</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEWDI-551</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI-551</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI-551</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI-551</intervention_name>
    <description>0.1 mg/kg</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.3 mg/kg</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI-551</intervention_name>
    <description>1.0 mg/kg</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI-551</intervention_name>
    <description>3.0 mg/kg</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI-551</intervention_name>
    <description>10.0 mg/kg</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects

          -  Age ≥ 18 years of age at the time of screening

          -  Written informed consent and HIPAA authorization (applies to covered entities in the
             USA only) obtained from the subject/legal representative prior to performing any
             protocol-related procedures, including screening evaluations

          -  Must fulfill the American Rheumatism Association (American College of Rheumatology)
             preliminary classification criteria for systemic sclerosis

          -  Has at least moderate skin thickening (score of at least 2 by mRTSS) in at least one
             area suitable for repeat biopsy, such as on the arms, legs, or trunk

          -  Females of childbearing potential, unless surgically sterile (ie, bilateral tubal
             ligation, bilateral oophorectomy, or complete hysterectomy), has sterile male partner,
             is at least 2 years post menopause, or practices abstinence, must use 2 effective
             methods of avoiding pregnancy (including oral, transdermal, or implanted
             contraceptives, intrauterine device, female condom with spermicide, diaphragm with
             spermicide, cervical cap, or use of a condom with spermicide by the sexual partner),
             from screening, and must agree to continue using such precautions through the Early
             Discontinuation Visit/End of Study (Day 85, single-dose cohorts); cessation of birth
             control should not occur until 5 half-lives post-cessation of MEDI-551, 5 half-lives
             is estimated to be 75 days

          -  Men, unless surgically sterile, must use 2 effective methods of birth control with a
             female partner and must agree to continue using such contraceptive precautions from
             Day 1 through the Early Discontinuation Visit/End of Study (Day 85, single-dose
             cohorts) and for 5 half-lives post-cessation of MEDI-551, 5 half-lives is estimated to
             be 75 days

          -  Ability to complete the study period, including follow-up period through Day 85

          -  Willingness to forego other forms of experimental treatment during the study (Day 1
             through the Early Discontinuation Visit/End of Study - Day 85, single-dose cohorts)

        Exclusion Criteria:

          -  History of allergic reactions to any component of the investigational product

          -  History of coagulation disorders that in the opinion of the investigator would
             contraindicate skin biopsies

          -  Has a body weight ≥ 120 kg or &lt; 40 kg

          -  Has B-cell count in peripheral blood &lt; 50% lower limit of normal (LLN) at screening

          -  Forced vital capacity (FVC) &lt; 55% predicted, diffusing capacity for carbon monoxide
             (DLCO) &lt; 40% predicted, pulmonary hypertension requiring treatment with endothelin
             receptor antagonists or prostacyclin analogues

          -  Scleroderma renal crisis within the last year, or medically significant malabsorption

          -  Receipt of any B-cell-depleting biologic therapies at any time, such as rituximab

          -  Receipt of leflunomide &gt; 20 mg/day within 6 months prior to randomization into the
             study

          -  Receipt of the following concomitant medications within 21 days prior to randomization
             into the study:

               -  Prednisone &gt; 30 mg/day or &gt; 0.5 mg/kg

               -  Cyclophosphamide

               -  Systemic cyclosporine

               -  Thalidomide

               -  Hydroxychloroquine &gt; 600 mg/day

               -  Mycophenolate mofetil &gt; 3 g/day

               -  Methotrexate &gt; 25 mg/week

               -  Azathioprine &gt; 3 mg/kg/day

               -  Concomitant methotrexate and leflunomide

               -  Any investigational drug therapy or non-B-cell-depleting biologic therapy (or
                  within 5 half-lives of ingestion, whichever is longer)

          -  Change in standing daily dosage of the following within 21 days before randomization
             into the study:

               -  Antimalarials

               -  Mycophenolate mofetil

               -  Methotrexate

               -  Leflunomide

               -  Azathioprine

               -  Systemic corticosteroids

          -  At screening blood tests (within 21 days prior to randomization into the study), any
             of the following:

               -  Aspartate aminotransferase (AST) &gt; 1.5 × upper limit of the normal range
                  (ULN)unless due to documented myositis

               -  Alanine aminotransferase (ALT) &gt; 1.5 × ULN unless due to documented myositis

               -  Total bilirubin &gt; ULN, unless because of known Gilbert's disease - Total
                  immunoglobin &lt;500 mg/dl

               -  Creatinine &gt; 2.5 mg/dL

               -  Neutrophils &lt; 1,500/mm3

               -  Platelet count &lt; 75,000/mm3

               -  Hemoglobin (Hgb) &lt; 8 g/dL

               -  Hemoglobin A1c (HbA1c) &gt; 8% at screening (diabetic subjects only)

               -  Positive serum βHCG (pregnancy test)

          -  Lactating woman

          -  Herpes zoster infection within 3 months before randomization

          -  A history of severe viral infection as judged by the investigator, including severe
             infections of either cytomegalovirus or the herpes family such as disseminated herpes,
             herpes encephalitis, ophthalmic herpes

          -  At screening, positive tests for active hepatitis A, hepatitis B surface antigen
             (HbsAg), Hepatitis B core antibody (HbcAb) or hepatitis C serology, or human
             immunodeficiency virus-1 or -2 (HIV-1/2). False positive tests are not included.

          -  Deep space/tissue infection (eg, fasciitis, abscess, osteomyelitis, or infected joint
             replacements) within 1 year before randomization into the study

          -  Any opportunistic infection or serious infection (in the opinion of the investigator)
             within 6 months prior to screening

          -  Any of the following within 21 days before randomization into the study:

               -  Clinically significant active infection, including ongoing, chronic infection

               -  Any infection requiring hospitalization or treatment with IV anti-infectives

          -  Completion of a course of oral anti-infectives within 14 days before randomization
             into the study

          -  Any acute illness or evidence of clinically significant active infection, such as
             fever ≥ 38.0 degrees C (≥ 100.5 degrees F) at screening or at Day 1

          -  Evidence of active tuberculosis (TB), either treated or untreated, or latent TB
             without completion of an appropriate course of treatment or appropriate ongoing
             prophylactic treatment. Evaluation and treatment will be according to the local
             standard of care and may consist of history and physical examinations, and/or chest X
             ray, and/or TB test (eg. purified protein derivative) testing, with the standard of
             care as determined by local guidelines

          -  History of primary immunodeficiency or underlying condition that predisposes the
             subject to infection (eg, splenectomy)

          -  Receipt of any live or attenuated vaccine within 21 days before randomization into the
             study or anticipated to be given within 5 half-lives of the last dose of
             investigational product administration, half-life is estimated to be approximately 15
             days. Therefore, receipt of live attenuated vaccine should be avoided for 75 days post
             dose of investigational product

          -  Medically indicated adult immunizations that are not current (eg, pneumococcal
             vaccine)

          -  Current evidence of alcohol, drug or chemical abuse, or a recent history of such abuse
             &lt; 1 year prior to randomization into the study

          -  History of cancer except basal cell carcinoma treated with apparent success with
             curative therapy ≥ 1 year prior to randomization into the study

          -  Major surgery within 8 weeks before randomization into the study or elective surgery
             planned from screening through the Early Discontinuation Visit/End of Study (Day 85,
             single-dose cohorts)

          -  History of any disease, evidence of any current disease (other than scleroderma), any
             finding upon physical examination, chest x-ray, or any laboratory abnormality that, in
             the opinion of the investigator or medical monitor, may compromise the safety of the
             subject in the study or confound the analysis of the study

          -  Any institutionalized individual

          -  Employees of the clinical study site or any other individuals involved with the
             conduct of the study, or immediate family members of such individuals

          -  Concurrent enrollment in another clinical study with the exception of observational or
             interventional studies that do not involve therapeutic strategies or invasive
             diagnostic tests

          -  Concurrent enrollment in another clinical study with an investigational product
             administered within 4 weeks prior to Day 1 or within 5 half-lives of the
             investigational product, whichever is longer

          -  Known sensitivity to acetaminophen/paracetamol, diphenhydramine, and
             methylprednisolone or equivalent glucocorticoid
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2009</study_first_submitted>
  <study_first_submitted_qc>July 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2009</study_first_posted>
  <last_update_submitted>November 11, 2014</last_update_submitted>
  <last_update_submitted_qc>November 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Scleroderma, Localized</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

